FDA approves Pfizer’s first gene therapy for rare inherited bleeding disorder
Publishing timestamp: 2024-04-26 09:22:54
Summary
The FDA approved Pfizer's gene therapy treatment for hemophilia B, making it the company's first gene therapy to win clearance in the U.S. The treatment, marketed as Beqvez, has a hefty $3.5 million price tag before insurance and other rebates. The approval is a big step for Pfizer as it looks to regain its footing following the decline of its Covid business last year. Pfizer is betting big on gene and cell therapies, with Beqvez competing with Australia-based CSL Behring's Hemgenix.
Sentiment: POSITIVE
Tickers: PFE,
Keywords: breaking news, pharmaceuticals, business, science, biotechnology, health care industry, business news, biotech and pharmaceuticals, united states, pfizer inc,